A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT01959282 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Placebo
DRUG: JNJ-54781532 25 mg once daily
DRUG: JNJ-54781532 75 mg once daily
DRUG: JNJ-54781532 150 mg once daily
DRUG: JNJ-54781532 75 mg twice daily

Sponsor

Janssen Research & Development, LLC